Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers

被引：6

作者：

Humeniuk, Michael S. ^{[1
]}

Zhang, Tian ^{[1
,2
]}

Armstrong, Andrew J. ^{[2
,3
,4
,5
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[2] Duke Canc Inst, Durham, NC USA

[3] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA

[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA

[5] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA

来源：

CANCER | 2017年 / 123卷 / 18期

关键词：

MEN; SURVIVAL;

D O I：

10.1002/cncr.30806

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The report in this issue by Pomerantz and colleagues demonstrates that men with metastatic prostate cancer harboring germline BRCA2 mutations are strongly associated with a prostate-specific antigen response 50% during treatment with a platinum agent. However, more work will be required to classify other men who might benefit from platinum agents. See also pages 3532-9.

引用

页码：3441 / 3444

页数：4

共 50 条

[31] DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy in colorectal cancer
Lin, Yan
Zhang, Jinyan
Liao, Xiaoli
Zhang, Yumei
Luo, Min
Li, Qian
Xie, Mingzhi
Liang, Chaoyong
Liao, Sina
Zheng, Yating
Hu, Xue
Huang, Mengli
Liang, Rong
Li, Yongqiang
CANCER RESEARCH, 2022, 82 (12)
[32] Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Karzai, Fatima
VanderWeele, David
Madan, Ravi A.
Owens, Helen
Cordes, Lisa M.
Hankin, Amy
Couvillon, Anna
Nichols, Erin
Bilusic, Marijo
Beshiri, Michael L.
Kelly, Kathleen
Krishnasamy, Venkatesh
Lee, Sunmin
Lee, Min-Jung
Yuno, Akira
Trepel, Jane B.
Merino, Maria J.
Dittamore, Ryan
Marte, Jennifer
Donahue, Renee N.
Schlom, Jeffrey
Killian, Keith J.
Meltzer, Paul S.
Steinberg, Seth M.
Gulley, James L.
Lee, Jung-Min
Dahut, William L.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[33] Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
Aldea, M.
Lam, L.
Llacer Perez, C.
Saint-Ghislain, M.
Gravis Mescam, G.
Flechon, A.
Roubaud, G.
Barthelemy, P.
Ricci, F.
Priou, F.
Neviere, Z. M.
Beaufils, M.
Helissey, C.
Ratta, R.
Pobel, C.
Castro Marcos, E.
Thiery-Vuillemin, A.
Baciarello, G.
Orillard, E.
Fizazi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S510 - S510
[34] Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1
Rajarajan, Savitha
Anupama, C. E.
Jose, Betsy
Correa, Marjorie
Sengupta, Sagar
Prabhu, Jyothi S.
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (05) : 1 - 8
[35] COST-EFFECTIVENESS OF OLAPARIB AS A MAINTENANCE TREATMENT OPTION FOR NEWLY DIAGNOSED BRCA-MUTATED OVARIAN CANCER WHO ARE IN RESPONSE AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PANAMA
Castillo-Fernandez, O.
Murtiera, S.
Solorzano, J.
Martin, C.
Amador Sosa, J. L.
Lim Law, M.
Veliz Centella, I
Cercone, J.
Leon, A.
VALUE IN HEALTH, 2020, 23 : S38 - S38
[36] Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib
Hong, Christopher
Sule, Amrita
Beckta, Jason
Sundaram, Ranjini
Bindra, Ranjit
CANCER RESEARCH, 2020, 80 (16)
[37] Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Tan, D. S.
Chan, J. J.
Loke, J. K.
Hettle, R.
Ghosh, W.
Viswambaram, A.
Yu, C. C.
ANNALS OF ONCOLOGY, 2019, 30
[38] Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Tan, David S. P.
Chan, Jack Junjie
Hettle, Robert
Ghosh, Wrik
Viswambaram, Amrita
Yu, Cindy Chen
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 14
[39] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
Penson, R. T.
Valencia, R. V.
Cibula, D.
Colombo, N.
Ill, C. L.
Bidzinski, M.
Kim, J. W.
Nam, J. H.
Madry, R.
Hernandez, C. H.
Mora, P.
Ryu, S. Y.
Milenkova, T.
Lowe, E.
Barker, L.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
[40] OLAPARIB COST-EFFECTIVENESS AS A MAINTENANCE TREATMENT OPTION FOR NEWLY DIAGNOSED BRCA-MUTATED OVARIAN CANCER WHO ARE IN RESPONSE AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN COSTA RICA
Molina Hernandez, J. P.
Solorzano, J.
Murtiera, S.
Perichon, S.
Cercone, J.
Leon, A.
VALUE IN HEALTH, 2020, 23 : S40 - S40

← 1 2 3 4 5 →